Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2010
11/02/2010US7825090 Dietetics; insulin resistance; diabetes; obesity; dietetics; packages
11/02/2010US7825089 Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto
11/02/2010US7825088 Methods for the treatment of multiple myeloma
11/02/2010US7825087 Nanoparticulate and controlled release compositions comprising cyclosporine
11/02/2010US7825086 Acyclovir-peptide analogs
11/02/2010US7825085 Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells
11/02/2010US7825084 human dietary supplement, comprising beta-alanine in unit dosage; regulating hydronium ion concentration; increasing beta-alanylhistidine dipeptide; insulin
11/02/2010US7825083 Synovial fluid barrier
11/02/2010US7824923 Screening for drugs which alter the amount, localization and/or characteristics of differentiation factors; use in enhancing the memory performance
11/02/2010US7824896 Modified subtilisin comprising reduced allergenicity for enhancing wash and cleaning performance of detergents and oral care products
11/02/2010US7824895 Phytases, nucleic acids encoding them and methods for making and using them
11/02/2010US7824886 DNA replication factors
11/02/2010US7824868 inducing formation of a conformationally distinct superfibronectin by contacting plasma fibronectin with BBK32 protein or a BBK32 peptide; treating pathophysiological conditions associated with endothelial cell proliferation and of inhibiting angiogenesis using the BBK32 protein
11/02/2010US7824860 Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (EAOH)
11/02/2010US7824851 With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region
11/02/2010US7824712 Method for reducing the likelihood of implantation failure during an assisted reproduction in a subject in need thereof
11/02/2010US7824709 Bioactive agent delivery particle comprising a lipid binding polypeptide, a lipid bilayer, and a bioactive agent, wherein interior of lipid bilayer comprises a hydrophobic region, and wherein bioactive agent is associated with hydrophobic region of lipid bilayer
11/02/2010US7824695 recombinant proteins comprise cell recognition moiety that binds alpha 2 macroglobulin receptor, and bioactive moiety (pseudomonas exotoxin), which mediates systemic effect, does not function as immunogen and does not have ADP ribosylating activity
11/02/2010US7824694 decreasing dose of headache medication (acetaminophen) via titration process in reverse of dosing regimen, locally administering botulin toxin; pharmacokinetics
11/02/2010US7824693 administering Botulinum toxin
11/02/2010US7824691 RNAIII-inhibiting peptide (RIP) with antimicrobial peptide such as cathelicidin, capable of binding and neutralizing lipidic and polyanionic components of bacterial cell envelope; infections from Staphylococcus and Bacillus; antibiotic resistance; cellulitis, keratitis, osteomyelitis, septic arthrititis
11/02/2010US7824688 Glucan-based vaccines
11/02/2010US7824687 Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
11/02/2010US7824686 Vaccines with enhanced immune response and methods for their preparation
11/02/2010US7824683 Methods for augmenting an immune response using anti-CD40 antibodies
11/02/2010US7824682 Dna sequence and genomic structure of human cardiac isoform; gene or allele mutants associated with cardiovascular disorders; reduce stretch activation and adjust tension of muscles in heart contraction; isolated nucleic acid encoding a protein
11/02/2010US7824680 Methods for inhibiting angiogenesis
11/02/2010US7824677 inhibiting blood coagulation mediated by factor X binding to tissue factor; provide superior anti-coagulant activity by binding native human tissue factor with high affinity and specificity; linked covalently to a cell antigen or an effector molecule to provide complement fixing ability
11/02/2010US7824674 An antibody for treating Crohn's disease and ulcerative colitis, inhibit the transduction of biological activity of cytokine, B-cell differentiation factors
11/02/2010US7824673 Supplying collagenase, protease to tissue; for removing excess amounts of unaesthetic and/or redundant subcutaneous adipose tissue; lipomas
11/02/2010US7824670 Use of il6r/il6 chimera in nerve cell regeneration
11/02/2010US7824669 administering a composition comprising a GM-CSF cysteine mutein of SEQ ID NO:8, wherein a cysteine residue is substituted for an amino acid selected from the group consisting of A1, A3, S5, S7, N27, T32, A33, E51, R67, S69, E93, T94, T98, Q99, T102, E123, V125, Q126, and E127
11/02/2010CA2623449C A novel use of bivalirudin in the treatment of acute coronary syndrome
11/02/2010CA2596977C Pyy agonists and uses thereof
11/02/2010CA2559745C Use of relaxin to increase arterial compliance
11/02/2010CA2471521C Novel microsphere and method for production thereof
11/02/2010CA2459690C Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process
11/02/2010CA2417432C Modified polypeptides stabilized in a desired conformation and methods for producing same
11/02/2010CA2360252C Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
11/02/2010CA2337422C Preventing airway mucus production by administration of egf-r antagonists
11/02/2010CA2281049C Water-soluble pharmaceutical composition in an ionic complex and the use thereof
11/02/2010CA2253246C Purified multimerase
11/02/2010CA2181394C Ctla4 mutant molecules and uses thereof
11/02/2010CA2150555C Cloning and expression of biologically active alpha-galactosidase a
11/01/2010CA2665302A1 Cd36 modulation and uses thereof
10/2010
10/28/2010WO2010124296A2 Compositions containing hc•ha complex and methods of use thereof
10/28/2010WO2010124280A2 Human serum albumin-based topical ointment for treatment of acne, psoriasis, egfr-induced toxicity, premature skin aging and other skin conditions
10/28/2010WO2010124259A1 Allosteramers for tnf receptors and uses thereof
10/28/2010WO2010124220A1 Method and composition for synchronizing time of insemination
10/28/2010WO2010124180A1 Phenylalanine hydroxylase fusion protein and methods for treating phenylketonuria
10/28/2010WO2010124085A2 Compositions and methods for preventing and treating uterine disease
10/28/2010WO2010124058A1 Compositions for use in the treatment of chronic obstructive pulmonary diseases and asthma
10/28/2010WO2010123947A2 Silk fibroin hydrogels and uses thereof
10/28/2010WO2010123946A2 Silk fibroin hydrogels and uses thereof
10/28/2010WO2010123945A2 Silk fibroin hydrogels and uses thereof
10/28/2010WO2010123930A2 Chemosensory receptor ligand-based therapies
10/28/2010WO2010123527A2 Use of epidermal growth factor inhibitors in the treatment of viral infection
10/28/2010WO2010123519A1 Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
10/28/2010WO2010123386A1 Method of preparing low-iron lactoferrin
10/28/2010WO2010123065A1 Cancer antigen helper peptide
10/28/2010WO2010122961A1 Method for preparing cell pharmaceutical
10/28/2010WO2010122482A1 Pharmaceutical compositions for the treatment of nasal polyposis
10/28/2010WO2010122385A1 Fast-acting insulin formulation
10/28/2010WO2010122378A1 Method for chondrogenic differentiation of pluripotent or multipotent stem cells using wnt6
10/28/2010WO2010122367A2 Meganuclease variants cleaving the genomic insertion of a virus and uses thereof
10/28/2010WO2010122164A1 VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
10/28/2010WO2010122135A2 Use of mlkl in cancer therapy
10/28/2010WO2010121559A1 Novel exendin variant and conjugate thereof
10/28/2010WO2010121361A1 Tissue kallikrein for the treatment of huntington's disease
10/28/2010WO2010121358A1 Tissue kallikrein for the treatment of schizophrenia and bipolar disorder
10/28/2010WO2010121352A1 Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
10/28/2010WO2010121351A1 Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
10/28/2010WO2010121334A1 Active substances-carrying pharmaceutical composition
10/28/2010WO2010121323A1 Method for the production of commercial nanoparticle and microparticle powders
10/28/2010WO2010093941A3 COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS
10/28/2010WO2010093925A3 Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
10/28/2010WO2010083504A3 Therapeutic charge engineered variants of lysozyme and methods for using same to treat infections
10/28/2010WO2010083051A9 Cartilage particle tissue mixtures optionally combined with a cancellous construct
10/28/2010WO2010078325A3 Natriuretic polypeptides for reducing or preventing restenosis
10/28/2010WO2010078285A3 Pharmaceutical compositions and methods of treating neurological insults
10/28/2010WO2010071824A3 Methods related to modified glycans
10/28/2010WO2010060104A3 Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone praticles as scaffolds for tissue regeneration
10/28/2010WO2010042755A3 Chimeric therapeutics, compositions, and methods for using same
10/28/2010WO2010042751A3 Chimeric therapeutics, compositions, and methods for using same
10/28/2010WO2010042749A3 Chimeric therapeutics, compositions, and methods for using same
10/28/2010WO2010042743A3 Chimeric multiplexes, compositions, and methods for using same
10/28/2010WO2010018378A8 Vaccine comprising amb a 1 peptides for use in the treatment of ragweed allergy
10/28/2010WO2009135615A8 Means for the treatment and/or prophylaxis of an autoimmune disease and for the formation of regulatory t-cells
10/28/2010US20100274362 Cartilage particle tissue mixtures optionally combined with a cancellous construct
10/28/2010US20100273990 Notch-based fusion proteins and uses thereof
10/28/2010US20100273989 Angiotensin converting enzyme homolog and uses therefor
10/28/2010US20100273986 Post-translational modification and clostridial neurotoxins
10/28/2010US20100273985 Post-translational modifications and clostridial neurotoxins
10/28/2010US20100273977 Process for the preparation of echinocandin derivatives
10/28/2010US20100273866 Diagnosis and treatment of cancer: i
10/28/2010US20100273862 Phosphatases which activate map kinase pathways
10/28/2010US20100273860 MODULATION OF APOLIPOPROTEIN (a) EXPRESSION
10/28/2010US20100273843 Heterocyclic self-immolative linkers and conjugates
10/28/2010US20100273817 Anti-cancer cyclopenta(g)quinazoline compounds
10/28/2010US20100273724 Pegylated ion channel modulating compounds
1 ... 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 ... 3163